In a mouse model of obesity, a one-time, single-dose pancreatic gene therapy sustained weight loss and glucose benefits that were otherwise reversed with semaglutide withdrawal.
An experimental pancreatic gene therapy given to a mouse model of obesity as a one-time, single-dose treatment showed improvements in body composition and fasting glucose comparable with those achieved with the glucagon-like peptide 1 receptor agonist semaglutide, without the reversal of fat-loss and glycemia improvements that are a key concern with the withdrawal of GLP-1 receptor agonist drugs.
The mice were randomized to receive either a single-dose administration of the pancreatic gene therapy , daily subcutaneous semaglutide injections , pancreatic gene therapy placebo , or a semaglutide placebo . At 4 weeks, semaglutide was discontinued, and five of the 10 mice in that group were randomized to the gene therapy, while the other five received placebo.At week 4, the pancreatic gene therapy arm had a reduction in fat mass of 21% compared with 16% with semaglutide 's 84th Scientific Sessions.The pancreatic gene therapy is in early development and has not been assessed by any regulatory body for investigational or commercial use.
Obese Genomics Genomic Medicine Gene Therapy Biologic Therapy Biologics Weight Loss Weight Management
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA expands approval of first gene therapy for rare form of muscular dystrophyThe Muscular Dystrophy Association trusts the decision of the FDA, which weighs the risks and benefits of the drug.
Read more »
6 Ways To Engineer Adenoviruses For Gene Therapy And VaccinesI am a scientist, businessman, author, and philanthropist. For nearly two decades, I was a professor at Harvard Medical School and Harvard School of Public Health where I founded two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology.
Read more »
Gene Therapy Improves Vision in Rare, Inherited Eye DisorderEDIT-101, a CRISPR-based gene editing therapy, shows promise in patients with retinal degeneration linked to CEP290 mutations.
Read more »
Another Study Finds CRISPR Gene Therapy Fights Sickle CellThere's more good news in the battle against sickle cell disease, with another trial finding CRISPR gene-editing therapy delivering impressive results for patients.
Read more »
Beta Thalassemia: Pricey Gene Therapy Hits the MarkAn FDA-approved gene therapy for the rare blood disorder was effective but came at an incredible expense.
Read more »
What New Gene Therapy Means For Sickle Cell PatientsDr. Omer Awan MD MPH CIIP is a practicing radiologist physician in Baltimore, MD that writes about healthcare and public health. He earned his Medical Doctor (MD) degree from the George Washington University School of Medicine and Health Sciences and his Master in Public Health (MPH) degree from Harvard University.
Read more »